The Netherlands: Lonza adds ADC technology platform with Synaffix acquisition

Basel Tower, Switzerland - Lonza Corporate

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, has acquired Synaffix, a Dutch biotechnology company focused on commercializing its clinical-stage technology platform for the development of antibody-drug conjugates (ADC). Synaffix revenues and margins will be recognized within the Lonza business from the date of acquisition. The acquisition comprises an initial €100m…

You must be a HMI Subscriber to view this content.

Subscribe Now »